Please assess the completion status of the following clinical trial:

Trial Title: Clobazam in Subjects With Lennox-Gastaut Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject must have been \<11 years of age at the onset of LGS~* Subject must have LGS~* Subject must be on at least 1 stable dose AED~* Parent or caregiver must be able to keep an accurate seizure diary~Key Exclusion Criteria:~* Etiology of subject's seizures is a progressive neurologic disease. Subjects with tuberous sclerosis will not be excluded from study participation~* Subject has had an episode of status epilepticus within 12 weeks of baseline~* Subject has had an anoxic episode requiring resuscitation within 1 year of screening~* Subject has had a clinically significant history of an allergic reaction or significant sensitivity to benzodiazepines~* Subject is taking more than 3 concurrent AEDs. Note: Vagal Nerve Stimulation (VNS) or ketogenic diet is allowed and each will be counted as one of the three allowed AEDs~* If the subject is on the ketogenic diet, has been for less than 4 weeks prior to screening or suffers from frequent stooling~* If the subject has a VNS, the settings have not been stable for at least 4 weeks prior to screening~* Subject has taken corticotropins in the 6 months prior to screening~* Subject is currently taking long-term systemic steroids (excluding inhaled medication for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception will be made of prophylactic medication, for example, for urinary tract infections or asthma~* If the subject is taking felbamate, has been taking it for less than 1 year prior to screening or previous treatment with felbamate resulted in withdrawal due to liver or bone marrow adverse events

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Clobazam Low Dose (Type: EXPERIMENTAL): None
- Clobazam High Dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).